SCHEMBL6174454

SCHEMBL6174454

Nc1nc(-c2ccc(NC(=O)CN(C(=O)c3ccc(F)cc3)c3ccc4snnc4c3)cc2)cs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.44
▸ TP53 P04637 2/20 0.44
▸ RAB9A P51151 9/20 0.42
▸ MEN1 O00255 6/20 0.42
▸ KMT2A Q03164 6/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ POLB P06746 3/20 0.42
▸ GAA P10253 1/20 0.42
▸ NPC1 O15118 7/20 0.41
▸ TDP1 Q9NUW8 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ LMNA P02545 1/20 0.39
▸ GFER P55789 1/20 0.39
▸ MCL1 Q07820 1/20 0.39
▸ NOX1 Q9Y5S8 1/20 0.39
▸ ALOX5 P09917 2/20 0.39
▸ PRMT3 O60678 1/20 0.38
▸ SMN1; SMN2 Q16637 4/20 0.38
▸ GRM1 Q13255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6174368 0.89 KMT2A (0.42) MAPTRAB9AMEN1KMT2AALDH1A1
Hydrochloric Acid SCHEMBL6173338 0.87 RAB9A (0.50) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL6174481 0.85 RAB9A (0.48) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL27583802 0.84 KMT2A (0.48) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL27601320 0.83 MEN1 (0.48) MAPTRAB9AMEN1KMT2AALDH1A1
Hydrochloric Acid SCHEMBL6174792 0.83 MEN1 (0.48) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL6173268 0.83 RAB9A (0.43) MAPTTP53RAB9AMEN1KMT2A
SCHEMBL6171748 0.82 RAB9A (0.43) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL6172214 0.82 MAPT (0.51) MAPTTP53RAB9AMEN1KMT2A
SCHEMBL6174882 0.82 POLB (0.49) MAPTTP53RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949543-B2 Amide derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-27 — — US claimed
EP-1340750-B1 AMIDE DERIVATIVES YAMANOUCHI PHARMA CO LTD (JP) 2005-08-17 — — EP claimed
US-20040034232-A1 Amide derivative ASTELLAS PHARMA INC. (JP) 2004-02-19 — — US claimed
EP-1340750-A1 AMIDE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-09-03 — — EP claimed
US-6949543-B2 Amide derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-27 — — US disclosed
EP-1340750-B1 AMIDE DERIVATIVES YAMANOUCHI PHARMA CO LTD (JP) 2005-08-17 — — EP disclosed
US-20040034232-A1 Amide derivative ASTELLAS PHARMA INC. (JP) 2004-02-19 — — US disclosed
EP-1340750-A1 AMIDE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-09-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034232-A1 Amide derivative HDAC2, ZC3HAV1, HDAC4 MAPT 1746/4885TP53 3080/4885RAB9A 1475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback